Pay in 4 interest-free payments of $5.28 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
L., Hertzmark, E., et al
51.5% 1 More likely to be commercially insured Prescriber trends Primary care (family) physicians were the most predominant prescribers in 2022, followed by endocrinologists Specialists prescribed semaglutide therapy for commercial enrollees more frequently than for managed Medicaid, indicating barriers to specialty care for lower-income patients Provider Specialties by Label Status Cohorts Observations on Specialist Trends Interventional cardiology emerged as a significant prescribing specialty for semaglutide therapy in both 2022 and 2023
These comparisons highlight the dynamic nature of obesity treatment research and the potential for continued innovation in this field
It is essential to familiarize oneself with the terms of the insurance policy, including exclusions and requirements for prior authorization
Response To "Superior Cerebrovascular Outcomes with Tirzepatide Versus Semaglutide: A [PMID: 41317265] Laboratory literature summary: Response To "Superior Cerebrovascular Outcomes with Tirzepatide Versus Semaglutide: A Call for Cautious Interpretation of Observational
US$ 22.48
US$ 20.19
,aspect=ignore)
US$ 25.18
US$ 24.53
